Table 1.
Characteristics of HIV-positive women in the cohort: N = 218.
| CHARACTERISTICS | N (%) | NO. OF WOMEN WITH ≥ 1 CERVICAL SCREENING TEST IN A 3-YEAR PERIOD (%) | OR DESCRIBING THE LEVEL ASSOCIATION BETWEEN SCREENING AND DETERMINANTS (95% CI) |
|---|---|---|---|
| Age at intake, y | |||
| • < 30 | 64 (29) | 47 (73) | reference |
| • 30–50 | 141 (65) | 73 (52) | 0.39 (0.20–0.74) |
| • > 50 | 13 (6) | 6 (46) | 0.31 (0.09–1.05) |
| HIV-endemic country* (N = 175) | |||
| • Not from endemic country | 54 (31) | 31 (57) | reference |
| • From endemic country | 121 (69) | 76 (63) | 1.25 (0.65–2.41) |
| CD4 cell count at intake, cells/μL (N = 217) | |||
| • < 200 | 71 (33) | 40 (56) | reference |
| • 200–500 | 91 (42) | 53 (58) | 1.08 (0.58–2.02) |
| • > 500 | 55 (25) | 32 (58) | 1.08 (0.53–2.20) |
| Most recent CD4 cell count, cells/μL | |||
| • < 200 | 44 (20) | 22 (50) | reference |
| • 200–500 | 80 (37) | 51 (64) | 1.76 (0.83–3.71) |
| • > 500 | 93 (43) | 53 (57) | 1.32 (0.64–2.72) |
| Viral load at intake, copies/mL (N = 217) | |||
| • <500 | 40 (18) | 19 (48) | reference |
| • 500–5000 | 75 (34) | 52 (69) | 2.50 (1.13–5.51) |
| • 5001–50 000 | 59 (27) | 31 (53) | 1.22 (0.55–2.73) |
| • > 50 000 | 43 (20) | 24 (56) | 1.40 (0.59–3.31) |
| Most recent viral load, copies/mL | |||
| • < 500 | 137 (63) | 88 (64) | reference |
| • 500–5000 | 31 (14) | 14 (45) | 0.46 (0.21–1.01) |
| • 5001–50 000 | 29 (13) | 16 (55) | 0.68 (0.30–1.54) |
| • > 50 000 | 20 (9) | 8 (40) | 0.37 (0.14–0.97) |
| No. of visits to tertiary care clinic (during 3-y study period) | |||
| • 1 | 16 (7) | 4 (25) | reference |
| • 2–5 | 55 (25) | 25 (45) | 2.50 (0.72–8.72) |
| • 6–9 | 46 (21) | 22 (48) | 2.75 (0.77–9.80) |
| • > 9 | 101 (46) | 75 (74) | 8.65 (2.56–29.20) |
| OHIP status | |||
| • Not insured by OHIP | 26 (12) | 8 (31) | reference |
| • Insured by OHIP | 192 (88) | 118 (61) | 3.59 (1.48–8.67) |
| Transmission risk group† | |||
| • Heterosexual (N = 216) | 208 (96) | 121 (58) | 2.32 (0.54–9.96) |
| • IVDU (N = 216) | 37 (17) | 20 (54) | 0.85 (0.42–1.73) |
| • Blood products (N = 216) | 27 (12) | 12 (44) | 0.55 (0.24–1.24) |
| • Other (eg, body piercing, tattoo) | 31 (14) | 16 (52) | 0.75 (0.35–1.60) |
| • Unknown | 6 (3) | 4 (67) | 1.48 (0.26–8.23) |
HIV—human immunodeficiency virus, IVDU—intravenous drug user, OHIP—Ontario Health Insurance Plan, OR—odds ratio.
*
According to the Public Health Agency of Canada.22
†
Categories are not mutually exclusive.